Canada Markets closed

PharmaTher Holdings Ltd. (PHRRF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2078-0.0122 (-5.55%)
At close: 03:43PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.2200
BidN/A x N/A
AskN/A x N/A
Day's Range0.1907 - 0.2132
52 Week Range0.1400 - 0.9890
Avg. Volume527,935
Market Cap14.346M
Beta (5Y Monthly)N/A
PE Ratio (TTM)6.70
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

    IRB approval to initiate Phase 2 study for methamphetamine abuse disorders Advancing psilocybin oral thin film, microneedle patch and biosynthesis programs TORONTO, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s psilocybin pharmaceutical de

  • GlobeNewswire

    PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS

    TORONTO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a company focused on the development and commercialization of specialty ketamine prescription-based products, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted an investigator-initiated investigational new drug ("IND") application to proceed with a Phase 2 clinical trial (the “Study”) evaluating ketamine in the treatment of Amyotrophic Late

  • GlobeNewswire

    PharmaTher Announces Publication of Research Data for KETABET™

    Second published study to demonstrate the potential therapeutic utility and mechanism of action of KETABET™ (patented combination of ketamine and betaine) in models of depression Repeated use of KETABET™ exhibits potential protective and reversing effects on ketamine-elicited psychotomimetic behaviors and cognitive impairments Supports clinical initiatives as a potential next generation ketamine treatment for mental health and pain disorders with patent protection into 2036 TORONTO, Jan. 04, 202